Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
NCT ID: NCT07164287
Last Updated: 2025-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
376 participants
OBSERVATIONAL
2020-06-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data will be analyzed from patients treated at the University Hospitals of Geneva between June 2020 and April 2025 who obtained individual authorizations from the Swiss Federal Office of Public Health for use of LSD or psilocybin under compassionate use criteria.
The main objective is to assess the effects of psychedelic-assisted psychotherapy with LSD or psilocybin on changes in depressive symptoms, anxiety symptoms. Secondary objectives include evaluating the association between psychedelic session intensity and the administered dose of LSD or psilocybin, changes in depressive symptoms, anxiety symptoms, and problematic substance use, as well as their association with intensity effects. Additionally physiological effects during session will be assessed.
All data are retrospectively collected from clinical records with prior patient consent.
This study aims to generate evidence on the feasibility, safety, and therapeutic potential of PAP in real-world clinical practice.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LSD Therapy for Persons Suffering From Major Depression
NCT03866252
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
NCT04670081
Psilocybin for Hospitalized Patients with Treatment-resistant Depression
NCT06378229
Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
NCT05175430
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
NCT03554174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subset Analysis: Cardiovascular Outcomes In addition to the main objectives, a subset analysis will be conducted to evaluate cardiovascular effects of LSD and psilocybin. Routinely collected data from 30 patients with treatment-resistant depression or anxiety disorders will be included.
Population: 30 patients who underwent their first psychedelic session (LSD 100-200 µg or psilocybin 15-25 mg).
Measurements: Heart rate and self-rated anxiety (visual analogue scale) recorded at seven time points between 30 and 300 minutes post-administration on the treatment day.
A further subset analysis investigated the role of early maladaptive schemas (EMS) in psychedelic-assisted psychotherapy.
Populations: 192 patients who routinely completed the Young Schema Questionnaire - Rasch version (YSQ-R) before treatment were included; of these, 97 initiated PAP with LSD or psilocybin and 74 contributed longitudinal outcomes.
Measurements: Baseline EMS profiles (YSQ-R) measured at Baseline (screening or preparation visit, before first psychedelic session), immediately after each psychedelic session (sessions 1-3, up to 9 months) and 1 month after each psychedelic session (sessions 1-3, up to 12 months after baseline).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lysergic Acid Diethylamide (LSD) or psilocybin
Psychedelic-assisted psychotherapy with LSD or psilocybin as a part of a clinical routine in our department
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of depressive, anxiety, or addictive disorder resistant to standard treatments.
* General consent for use of routinely collected clinical data.
* Federal Office of Public Health authorization for PAP.
Exclusion Criteria
* bipolar disorder
* high suicidal risk
* severe cardiovascular disease
* severe liver disease
* neurological disease of the central nervous system
* pregnancy
* breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Louise Penzenstadler
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geneva University Hospital
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID 2022-02015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.